Aprea Therapeutics (APRE) Competitors $1.44 +0.02 (+1.75%) Closing price 03:58 PM EasternExtended Trading$1.39 -0.05 (-3.72%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. KLTO, ITRM, MAAQ, TENX, RENB, KZR, RNTX, DARE, HOTH, and CVKDShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Klotho Neurosciences (KLTO), Iterum Therapeutics (ITRM), Mana Capital Acquisition (MAAQ), Tenax Therapeutics (TENX), Lunai Bioworks (RENB), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), Dare Bioscience (DARE), Hoth Therapeutics (HOTH), and Cadrenal Therapeutics (CVKD). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Its Competitors Klotho Neurosciences Iterum Therapeutics Mana Capital Acquisition Tenax Therapeutics Lunai Bioworks Kezar Life Sciences Rein Therapeutics Dare Bioscience Hoth Therapeutics Cadrenal Therapeutics Klotho Neurosciences (NASDAQ:KLTO) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Do analysts rate KLTO or APRE? Aprea Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 972.81%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Klotho Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Klotho Neurosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, KLTO or APRE? Klotho Neurosciences has a beta of 10.74, suggesting that its share price is 974% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Which has stronger earnings and valuation, KLTO or APRE? Klotho Neurosciences has higher earnings, but lower revenue than Aprea Therapeutics. Klotho Neurosciences is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKlotho NeurosciencesN/AN/A-$6.15M-$0.45-1.06Aprea Therapeutics$1.50M5.62-$12.96M-$2.32-0.62 Is KLTO or APRE more profitable? Klotho Neurosciences has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,645.01%. Aprea Therapeutics' return on equity of -78.90% beat Klotho Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Klotho NeurosciencesN/A -325.88% -242.15% Aprea Therapeutics -1,645.01%-78.90%-62.67% Does the media prefer KLTO or APRE? In the previous week, Klotho Neurosciences had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Klotho Neurosciences and 1 mentions for Aprea Therapeutics. Klotho Neurosciences' average media sentiment score of 1.91 beat Aprea Therapeutics' score of 1.89 indicating that Klotho Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Klotho Neurosciences Very Positive Aprea Therapeutics Very Positive Do institutionals and insiders have more ownership in KLTO or APRE? 20.1% of Klotho Neurosciences shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 26.7% of Klotho Neurosciences shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAprea Therapeutics beats Klotho Neurosciences on 8 of the 15 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.27M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.6220.6375.7726.11Price / Sales5.62442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book0.419.6212.876.30Net Income-$12.96M-$52.73M$3.29B$271.03M7 Day Performance-3.68%0.64%-0.26%-0.15%1 Month Performance-9.70%6.31%3.84%6.41%1 Year Performance-49.66%18.97%68.35%28.81% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics2.7795 of 5 stars$1.44+1.7%$15.50+972.8%-52.3%$8.27M$1.50M-0.627Positive NewsKLTOKlotho Neurosciences0.6054 of 5 stars$0.54-2.1%N/AN/A$33.05MN/A-1.20N/ANews CoveragePositive NewsITRMIterum Therapeutics2.6841 of 5 stars$0.70+2.8%$9.00+1,187.6%-29.7%$32.97MN/A-0.8210Gap UpMAAQMana Capital AcquisitionN/A$3.99+3.1%N/A+1,348.1%$32.42MN/A0.001TENXTenax Therapeutics2.4342 of 5 stars$6.57+2.2%$18.00+174.0%+90.6%$29.98MN/A-7.159Positive NewsRENBLunai Bioworks0.8086 of 5 stars$0.17+7.0%N/A-64.2%$29.78MN/A-0.2220Trending NewsUpcoming EarningsStock SplitGap DownHigh Trading VolumeKZRKezar Life Sciences3.8171 of 5 stars$3.96+3.5%$9.00+127.6%-31.2%$28.95M$7M-0.4160Positive NewsRNTXRein Therapeutics2.4683 of 5 stars$1.20+1.7%$10.00+733.3%N/A$27.97MN/A-0.459News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeDAREDare Bioscience2.2165 of 5 stars$2.07+1.5%$10.00+383.1%-33.7%$27.84M$10K-0.9630News CoverageHOTHHoth Therapeutics2.9472 of 5 stars$2.08+7.0%$4.00+92.8%+126.7%$27.52MN/A-1.944News CoverageCVKDCadrenal Therapeutics3.4343 of 5 stars$13.36+2.3%$32.00+139.6%+15.7%$27.38MN/A-1.504 Related Companies and Tools Related Companies KLTO Competitors ITRM Competitors MAAQ Competitors TENX Competitors RENB Competitors KZR Competitors RNTX Competitors DARE Competitors HOTH Competitors CVKD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APRE Stock Alerts